Format

Send to

Choose Destination
Int J Cardiol. 2019 Aug 1;288:137-139. doi: 10.1016/j.ijcard.2018.10.004.

Percutaneous treatment of mitral valve regurgitation: Where do we stand?

Author information

1
Department of Cardiovascular and Thoracic Surgery, San Raffaele University Hospital, Milan, Italy.
2
Department of Cardiovascular and Thoracic Surgery, San Raffaele University Hospital, Milan, Italy. Electronic address: alfieri.ottavio@hsr.it.

Abstract

Surgery has been the standard of care for mitral valve diseases to date. In the last fifteen years, due to increased aging of the population, with a great number of patients being high-risk for surgical treatment, transcatheter treatments for mitral valve disease have greatly developed. Further development and expansion of transcatheter treatments are expected. However, some limitations remain, such as efficacy and durability, which impact the widespread use of these devices.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center